A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

ABSTRACT: This is a Phase 1/2, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849 (adagrasib) in patients with advanced solid tumor malignancy harboring mutations in the KRAS, MAPK pathways.

DISEASE(S): Solid Tumor,Nsclc,Colorectal Cancer,Advanced Solid Tumor,Non Small Cell Lung Cancer,Colo-rectal Cancer,Carcinoma, Non-small-cell Lung,Neoplasms

PROVIDER: 2751259 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR